Dr. Robert D. Schreiber

• 
  www.irvingtoninstitute.org/news/news.html - [Cached Version]
  Published on: 11/18/2007    Last Visited: 12/22/2007  

  Cancer Research Institute Scientific Advisory Council Associate Director Robert D. Schreiber, Ph.D., alumni professor of pathology and immunology at Washington University School of Medicine in St. Louis, MO, and CRI supported colleagues there, in collaboration with CRI supported researchers and others at five other academic institutions in Australia, Europe, and the U.S., describe in the paper how they used a mouse model to show that the animal's immune system can keep tumor growth in check over an extended period.
  
  "Thanks to the animal model we have developed, scientists can now reproduce this condition of tumor dormancy in the laboratory and look directly at cancer cells being held in check by the immune system," says Dr. Schreiber.
  
  In 2001, Dr. Schreiber and colleagues published the first evidence that the immune system is involved in the control of cancer via a process called immunosurveillance.

• 
  www.igenica-inc.com/pages/igenica_robert_schreiber_2.ht - [Cached Version]
  Published on: 7/6/2009    Last Visited: 7/6/2009  

  Robert Schreiber, Ph.D. Igenica, Inc.
  ...
  Robert Schreiber, Ph.D.
  ...
  Robert Schreiber, Ph.D. Chairman
  ...
  Dr. Schreiber is the Alumni Endowed Professor of Pathology and Immunology, Professor of Molecular Microbiology and Tumor Immunology Program Leader for the Siteman Comprehensive Cancer Center at Washington University School of Medicine and an Affiliate of the Ludwig Institute for Cancer Research. He is a Fellow of the American Association of Science, an Associate Director of the Cancer Research Institute, a member of the Board of Scientific Advisors for the National Cancer Institute, and a past president of the Society for Leukocyte Biology. His lab is highly regarded for its research on the molecular cell biology and immunology of interferon-gamma and its receptor, as well as its strong expertise in mAb discovery. Dr. Schreiber's group unequivocally demonstrated that the immune system provides an extrinsic tumor suppressor function (cancer immunosurveillance) capable of eliminating spontaneous- and carcinogen-induced primary tumors.

• 
  info.cancerresearchuk.org/news/archive/newsarchive/2007 - [Cached Version]
  Published on: 11/20/2007    Last Visited: 11/28/2007  

  Dr Robert Schreiber, professor of pathology and immunology at the Washington University School of Medicine, commented: "Thanks to the animal model we have developed, scientists can now reproduce this condition of tumour dormancy in the laboratory and look directly at cancer cells being held in check by the immune system.
  ...
  Dr Schreiber explained: "Cancer is typically a disease of the elderly, who have moved beyond their reproductive years, so there probably was no evolutionary pressure for the immune system to find a way to fight cancer."

• 
  www.biospace.com/news_story.aspx?NewsEntityId=130578&So - [Cached Version]
  Published on: 3/9/2009    Last Visited: 3/13/2009  

  Co-founders Dr. Robert Schreiber from Washington University in St. Louis chairs the Scientific Advisory Board, and Dr. Guoqing Chen, formerly at Amgen, serves full time as VP of Research.
  ...
  Dr. Schreiber is an internationally recognized tumor immunologist. Dr. Chen comments, “It has been great to work with Dr. Schreiber; he brings decades of relevant expertise to our collaboration at Igenica.†The team has recruited several world renowned scientists and oncologists to the Scientific Advisory Board to guide the prioritization and development of Igenica’s programs.
  ...
  Igenica co-founder Dr. Schreiber represents the common shareholders on the Board.

• 
  www.sunsmart.org.au/aspx/news_article.aspx?id=138 - [Cached Version]
  Published on: 11/21/2007    Last Visited: 12/30/2007  

  A team led by Washington University School of Medicine Professor Robert Schreiber found some cancers are kept in a state of "equilibrium" for decades, unable to be completely wiped out but also unable to grow. The findings published today in the online version of science journal Nature came from a study of mice which were genetically engineered to develop cancer.Professor Schreiber said "thanks to the animal model we have developed, scientists can now reproduce this condition of tumour dormancy in the laboratory and look directly at cancer cells being held in check by the immune system."

• 
  immunochemotherapy.comm-sante.com/index.php?inscription - [Cached Version]
  Published on: 6/27/2008    Last Visited: 7/1/2008  

  10.00: Robert Schreiber (Washington University School of Medicine, St. Louis, MO, USA): Immunoediting and cancer dormancy
  ...
  Robert Schreiber Washington University School of Medicine

• 
  www.cancerresearch.org//designated_recipients.html - [Cached Version]
  Published on: 7/1/2005    Last Visited: 8/8/2007  

  Robert D. Schreiber, Ph.D.

• 
  www.cancervictors.net/resources/news.asp?filteryear=200 - [Cached Version]
  Published on: 11/1/2007    Last Visited: 12/2/2007  

  The researchers included graduate student Catherine Koebel and Robert Schreiber, PhD, of the pathology and immunology department at Washington University School of Medicine in St. Louis.

• 
  www.isbtc.org/meetings/am08/schedule.php - [Cached Version]
  Published on: 12/7/2007    Last Visited: 2/22/2008  

  Robert D. Schreiber, PhD - Washington University in St. Louis

• 
  www.irvingtoninstitute.org//wcancer/wcancerinfo.html - [Cached Version]
  Published on: 12/22/2007    Last Visited: 12/22/2007  

  Robert D. Schreiber, Ph.D., an Alumni Endowed Professor of Pathology at Washington University School of Medicine in St. Louis, Missouri, and Associate Director of the Institute's Scientific Advisory Council, is one of the major figures in the field of cancer immunology and is a significant contributor to the Institute's work.Dr. Schreiber's group proved conclusively several years ago that the immune system can and does routinely detect and destroy cancer cells over an individual's lifetime.Cancer can result when this natural immune suppression is disrupted.This "immunosurveillance" against cancer is the underpinning base of cancer immunology theory, and Dr. Schreiber's proof of it has galvanized the cancer immunology community and has helped to propel the field to the forefront of cancer treatment research.
  
  Dr. Schreiber continues to push forward our understanding of the immune system's relationship to cancer and has recently become actively involved in the fight against breast cancer.As the CRI/Rhea (Rose Marie) Finnell Memorial Clinical Investigator, Dr. Schreiber is conducting critical breast cancer research using a novel mouse mammary gland tumor model that was developed in his laboratory.
  ...
  By utilizing his unique mouse model, Dr. Schreiber has been able to define many of the developmental stages of breast cancer and has established several characteristics of the tumors that develop.Additionally, Dr. Schreiber has been instrumental in developing the means to study breast cancer cell lines outside of the human or animal body by manipulating tumors grown in the novel mouse model.

Page:  1 2 3 4 5